Video

Dr. Bhave on Promising Combination Strategies in TNBC

Manali Bhave, MD, discusses promising combination strategies in triple-negative breast cancer.

Manali Bhave, MD, assistant professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, medical oncologist, Winship Cancer Institute, discusses promising combination strategies in triple-negative breast cancer (TNBC).

Scientific rationale suggests that adding targeted therapies to immunotherapy could enhance neoantigen expression and enhance the efficacy of immunotherapy in patients with TNBC, says Bhave.

Moreover, combinations of targeted therapy and immunotherapy may yield less toxicity vs chemotherapy and could, improve quality of life for this patient population, concludes Bhave.

Related Videos
Yair Lotan, MD, UT Southwestern Medical Center
Alan Tan, MD, Vanderbilt-Ingram Cancer Center
Alex Herrera, MD
Roy S. Herbst, MD, PhD
Sheldon M. Feldman, MD
Laura J. Chambers, DO
Thomas Westbrook, MD
Massimo Cristofanilli, MD, attending physician, NewYork-Presbyterian Hospital; professor, medicine, Weill Cornell Medical College, Cornell University
Fred Saad, CQ, MD, FRCS, FCAHS, director, Prostate Cancer Research, Montreal Cancer Institute, Centre Hospitalier de l’Université de Montréal; full professor, Department of Surgery, Université de Montréal; uro-oncologist, Urology Department, University of Montreal Health Center
Ajay K. Nooka, MD, MPH, FACP